Medtronic glucose monitoring app now available for Android

Just over a year ago, Medtronic launched an iOS app that allows patients using its MiniMed continuous glucose monitor to view real-time data on their iPhones. Now, more patients will be getting on board as Medtronic debuts the Android version of the app.

The MiniMed Connect app connects with a patient’s insulin pump and MiniMed 530G or MiniMed Revel continuous glucose monitors and is updated with new data every five minutes. It is the first app that allows diabetics to monitor their real-time blood glucose levels on an Android device, Medtronic said in a statement. Caregivers may access real-time data from the app on any internet-connected mobile device or PC. Data from the app is also uploaded daily to the CareLink therapy management software, helping physicians optimize therapy, Medtronic said.

"In addition to greater convenience, our recent data shows that with easier and better access to their data, the MiniMed Connect app helps patients reduce high and low sugar events, and keep their sugar within range more often," said Annette Brüls, president of Medtronic’s Diabetes Service and Solutions division, in the statement. "Making the MiniMed Connect app available for Android users, their loved ones and their care partners propels us forward in our goal to meet both the diabetes management and lifestyle needs of people with diabetes so they can live with greater freedom and better health."


Join the world's top medtech executives virtually for the leading event in medtech — The Virtual MedTech Conference by AdvaMed

Expect the same high-quality education, world-class speakers and valuable business development in a virtual format. Experience more of the conference with on demand content and partnering, as well as livestreamed sessions.

After Medtronic launched the iOS app, it examined data from almost 2,800 patients who used it for at least 60 consecutive days. The data, collected in CareLink, showed that patients using the app had two fewer low blood sugar events and 41 fewer severe high blood sugar events per year, according to the statement. Additionally, 66% stayed in their acceptable blood glucose range more often.

The MiniMed app is just one facet of Medtronic’s mission to “transform” diabetes care. In January, Medtronic and IBM Watson unveiled the prototype of an app that could predict dangerously low blood glucose levels up to three hours in advance. And the devicemaker’s MiniMed 670G hybrid closed-loop system earned FDA approval this fall and is the first device approved anywhere that continuously measures blood glucose and delivers the appropriate amount of basal insulin.

Suggested Articles

Novartis is forging ahead with the development of spartalizumab in "many, many other indications" despite the setback.

Chi-Med has detailed plans to seek approval from the FDA later this year in part on the strength of data from Chinese phase 3 trial.

Takeda tapped Roche’s Foundation Medicine to develop tissue- and blood-based companion diagnostic tests for its portfolio of lung cancer therapies.